Last updated: April 30, 2026
Which companies supply methotrexate API or finished methotrexate products under the “LPF” label?
No complete, citable supplier list can be produced from the information provided. A “supplier” set depends on (1) the exact legal entity behind “LPF,” (2) country/market, and (3) whether “LPF” denotes an authorized distributor, a specific branded product line, a packaging/labeler code, or a formulation variant. Without those identifiers, any supplier attribution would be speculative and not suitable for patent-grade analysis.
What supplier categories exist for methotrexate used in pharmaceutical supply chains?
Even without mapping “LPF” to specific entities, the methotrexate supply chain typically separates into two supply categories:
- Methotrexate API manufacturers (active ingredient producers supplying under GMP/API distribution)
- Finished-dose manufacturers and labelers (formulation, packaging, and market authorization holders; may also include authorized distributors in specific countries)
What product forms and strengths matter for supply identification?
Supplier mapping requires the exact product configuration, because methotrexate supply differs by:
- Route: oral vs injectable
- Strength: mg per tablet/capsule or concentration per mL
- Salt/form: methotrexate (and related specifications used by each manufacturer)
- Pack size and labeler: often determines which legal entities appear on local regulatory listings
What patent-grade documentation is usually used to identify the right suppliers?
In practice, supplier identification for methotrexate products is anchored to regulatory and dossier-level evidence:
- Local marketing authorization records (MAH/labeler, manufacturing site, packager)
- US FDA Orange Book entries (if applicable) for product/labeler linkages
- EMA national registers (for EU member state authorizations)
- GMP certificates and inspection databases tied to the specific manufacturing site(s)
- Drug product listing databases where “labeler” appears as a distinct entity
How to interpret “LPF” in supplier terms
“LPF” must map to a real-world entity or scheme (for example: labeler, distributor, packaging facility, product family code, or a specific manufacturer’s internal code). The same methotrexate strength may list different manufacturing sites and labelers across regions, and the “LPF” mapping determines which suppliers are considered “the” suppliers.
Key Takeaways
- A defensible supplier list for “METHOTREXATE LPF” cannot be produced from the provided input because “LPF” is not uniquely identifiable in supplier terms.
- Supplier mapping for methotrexate must tie to the exact market authorization record or dossier where labeler/MAH and manufacturing sites are explicitly named.
- The supplier universe splits into API manufacturers and finished-dose manufacturers/labelers, and the correct set depends on the specific product configuration and labeling entity behind “LPF.”
FAQs
-
What does “LPF” usually mean on methotrexate product documents?
It can denote a labeler, distributor program, packaging/labeling identifier, or a product family code, but it cannot be resolved to a supplier set without the governing record.
-
Are methotrexate API suppliers the same as finished-product suppliers?
No. API manufacturers supply the active ingredient; finished-dose manufacturers and labelers handle formulation, packaging, and market authorization.
-
Why does the route (oral vs injectable) change the supplier list?
Different manufacturing lines, sterility requirements, and regulatory dossiers often map to different GMP sites and different labelers.
-
Where is the most reliable evidence of suppliers for a specific labeled methotrexate product?
In regulatory marketing authorization records (MAH/labeler and manufacturing site fields) tied to the exact product and market.
-
Can I compile suppliers from strength alone?
No. Strength without labeler/authorization identifiers typically yields multiple eligible manufacturing sites and labelers.
References
None.
